Kenneth W. Mahaffey, MD
Department / Division
Medicine /
Medicine - Cardiology
Address
DUMC 3850
Durham, NC 27710
2400 Pratt Street, Room 0311 Terrace Level
Durham, NC 27750
Appointment Telephone
919-681-5816
Office Telephone
919-668-8845
Fax Telephone
919-668-7059
- MD, University of Washington School of Medicine, 1989
- Internal Medicine, University of Arizona Health Sciences Center, Tucson VA Medical Center, 1989-1993
- Cardiology, Duke University Medical Center, 1993-1996
Clinical Interests
Acute coronary care, acute myocardial infarction, unstable angina, congestive heart failure
Research Interests
Dr. Mahaffey is also the Faculty Associate Director of the Duke Clinical Research Institute and Director of the MegaTrials and CEC Groups. His primary research focus is the design and conduct of multicenter clinical trails and analyses of important clinical cardiac issues using large patient databases. His research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies.
Dr. Mahaffey is also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events, and the conduct of large multinational clinical trials. The DCRI CEC and CV Mega-Trial groups are internationally recognized leaders and have developed efficient strategies to adjudicate clinical endpoints and conduct and manage operational features of global cardiovascular clinical trials.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Amgen, Inc.
- Bayer
- Bristol-Myers Squibb
- Cubist Pharmaceuticals, Inc.
- Daiichi Sankyo Co., Ltd
- Forest Pharmaceuticals (Forest Labs)
- GlaxoSmithKline
- Johnson & Johnson
- Lilly (Eli Lilly)
